BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical Study
← catalyst calendarSponsored by Becton, Dickinson and Company (industry) · BDX — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
156actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-28 | actual | When the study began enrolling |
| Primary completion | 2025-09-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-23 | actual | The whole study's end, after follow-up |
| First posted | 2024-10-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- BD Prevue II for Peripheral Intravenous Catheter Placement
Intervention
- Device: BD Prevue(TM) II
Primary outcomes
what the primary-completion date above is the date OFPrimary Performance: To provide visualization of the target vessel in which to insert the chosen vascular access device
measured During the procedure
Primary Performance: To have successful vascular access either by cannulation or blood return.
measured During the procedure
Primary Performance: To determine if BD Prevue(TM) II Peripheral Vascular Access System with Cue(TM) Needle Tracking Technology is able to provide visual needle tip location tracking to assist with insertion of the chosen vascular access device.
measured During the procedure
Primary Safety: To determine the incidence of device related adverse events, experienced by patient or user, when using the BD PrevueTM II Peripheral Vascular Access System with CueTM Needle Tracking Technology
measured During the procedure and 15 minutes after the procedure
Permalink · BDX's whole pipeline · Catalyst calendar · Every registered study · What changed